Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 3
1989 2
1990 1
1991 1
1992 2
1993 1
1994 1
1995 1
1996 3
1997 1
1998 1
1999 5
2000 13
2001 5
2002 8
2003 10
2004 6
2005 10
2006 8
2007 9
2008 17
2009 12
2010 22
2011 16
2012 22
2013 31
2014 26
2015 26
2016 30
2017 31
2018 29
2019 36
2020 44
2021 51
2022 39
2023 52
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

514 results

Results by year

Filters applied: . Clear all
Page 1
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches.
Svačina MKR, Lehmann HC. Svačina MKR, et al. Curr Pharm Des. 2022;28(11):854-862. doi: 10.2174/1381612828666220325102840. Curr Pharm Des. 2022. PMID: 35339172 Review.
Despite various established therapies and the current development of novel therapeutics, treatment of CIDP remains challenging due to an heterogeneous disease course and the lack of surrogate parameters to predict the risk of clinical deterioration. This review summarizes …
Despite various established therapies and the current development of novel therapeutics, treatment of CIDP remains challenging due to an het …
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Oaklander AL, et al. Cochrane Database Syst Rev. 2017 Jan 13;1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2. Cochrane Database Syst Rev. 2017. PMID: 28084646 Free PMC article. Review.
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic progressive or relapsing and remitting disease that usually causes weakness and sensory loss. ...Methotrexate may not be of benefit and IFN beta-1a is probably no …
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic progressive or relapsi …
Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
Hu J, Sun C, Lu J, Zhao C, Lin J. Hu J, et al. J Neurol. 2022 Mar;269(3):1250-1263. doi: 10.1007/s00415-021-10646-y. Epub 2021 Jun 12. J Neurol. 2022. PMID: 34120208 Review.
BACKGROUND: Current standard treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been proved effective, but it is poorly effective in refractory patients and unclear for anti-IgG4 antibody-associated CIDP. ...The standard …
BACKGROUND: Current standard treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has b …
Rituximab in refractory chronic inflammatory demyelinating polyneuropathy.
Muley SA, Jacobsen B, Parry G, Usman U, Ortega E, Walk D, Allen J, Pasnoor M, Varon M, Dimachkie MM. Muley SA, et al. Muscle Nerve. 2020 May;61(5):575-579. doi: 10.1002/mus.26804. Epub 2020 Jan 21. Muscle Nerve. 2020. PMID: 31922613
METHODS: Baseline and post-rituximab-therapy neuromuscular Medical Research Council (MRC) sum scores, Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, and functional status were assessed in 11 patients with refactory CIDP. RESULTS: The MRC sum …
METHODS: Baseline and post-rituximab-therapy neuromuscular Medical Research Council (MRC) sum scores, Inflammatory Neuropathy Cause a …
Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
van Doorn PA. van Doorn PA. Presse Med. 2013 Jun;42(6 Pt 2):e193-201. doi: 10.1016/j.lpm.2013.02.328. Epub 2013 Apr 28. Presse Med. 2013. PMID: 23628447 Review.
About 5% of patients initially diagnosed with GBS turn out to have chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with acute onset (A-CIDP). ...Advances in prognostic modelling resulted in the development of a simple prognostic scale …
About 5% of patients initially diagnosed with GBS turn out to have chronic inflammatory demyelinating polyradiculone …
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
Bril V, Hadden RDM, Brannagan TH 3rd, Bar M, Chroni E, Rejdak K, Rivero A, Andersen H, Latov N, Levine T, Pasnoor M, Sacconi S, Souayah N, Anderson-Smits C, Duff K, Greco E, Hasan S, Li Z, Yel L, Ay H. Bril V, et al. J Peripher Nerv Syst. 2023 Sep;28(3):436-449. doi: 10.1111/jns.12573. Epub 2023 Jul 6. J Peripher Nerv Syst. 2023. PMID: 37314318 Clinical Trial.
BACKGROUND AND AIMS: ADVANCE-CIDP 1 evaluated facilitated subcutaneous immunoglobulin (fSCIG; human immunoglobulin G 10% with recombinant human hyaluronidase) efficacy and safety in preventing chronic inflammatory demyelinating polyradiculoneuropathy ( …
BACKGROUND AND AIMS: ADVANCE-CIDP 1 evaluated facilitated subcutaneous immunoglobulin (fSCIG; human immunoglobulin G 10% with recombinant hu …
Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.
Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, Clodi E; ProCID Investigators. Cornblath DR, et al. Brain. 2022 Apr 29;145(3):887-896. doi: 10.1093/brain/awab422. Brain. 2022. PMID: 35038723 Free PMC article. Clinical Trial.
The primary end point was the response rate in the 1.0 g/kg group, defined as an improvement 1 point in adjusted Inflammatory Neuropathy Cause and Treatment score at Week 6 versus baseline and maintained at Week 24. Secondary end points included dose response and safety. . …
The primary end point was the response rate in the 1.0 g/kg group, defined as an improvement 1 point in adjusted Inflammatory Neuropathy Cau …
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, Blomkwist-Markens PH, Cornblath DR, Goedee HS, Harbo T, Jacobs BC, Kusunoki S, Lehmann HC, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Umapathi T, Topaloglu HA, Willison HJ. van Doorn PA, et al. J Peripher Nerv Syst. 2023 Dec;28(4):535-563. doi: 10.1111/jns.12594. Epub 2023 Oct 10. J Peripher Nerv Syst. 2023. PMID: 37814551 Review.
For diagnosis, the principal GPPs are: GBS is more likely if there is a history of recent diarrhoea or respiratory infection; CSF examination is valuable, particularly when the diagnosis is less certain; electrodiagnostic testing is advised to support the diagnosis; testing for a …
For diagnosis, the principal GPPs are: GBS is more likely if there is a history of recent diarrhoea or respiratory infection; CSF examinatio …
Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.
van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS. van Nes SI, et al. Neurology. 2011 Jan 25;76(4):337-45. doi: 10.1212/WNL.0b013e318208824b. Neurology. 2011. PMID: 21263135
OBJECTIVE: To develop a patient-based, linearly weighted scale that captures activity and social participation limitations in patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and gammopathy- …
OBJECTIVE: To develop a patient-based, linearly weighted scale that captures activity and social participation limitations in patients with …
POEMS syndrome.
Keddie S, Lunn MP. Keddie S, et al. Curr Opin Neurol. 2018 Oct;31(5):551-558. doi: 10.1097/WCO.0000000000000610. Curr Opin Neurol. 2018. PMID: 30138145 Review.
Simple treatment algorithms are based on the extent of monoclonal proliferation and the performance status of patients. Risk factors, prognostic scores, and their impact on outcome measures have been developed from deeply phenotyped patient cohorts to predict respon …
Simple treatment algorithms are based on the extent of monoclonal proliferation and the performance status of patients. Risk factors, progno …
514 results